142 related articles for article (PubMed ID: 37890334)
1. Generation of the iPSC line FINi002-A from a male Parkinson's disease patient carrying compound heterozygous mutations in the PRKN gene.
Pavan C; Jin J; Jong S; Strbenac D; Davis RL; Sue CM; Johnston J; Lynch T; Halliday G; Kirik D; Parish CL; Thompson LH; Ovchinnikov DA
Stem Cell Res; 2023 Dec; 73():103211. PubMed ID: 37890334
[TBL] [Abstract][Full Text] [Related]
2. Generation and characterization of induced pluripotent stem cell (iPSC) lines of two asymptomatic individuals carrying a heterozygous exon 7 deletion in Parkin (PRKN) and two non-carriers from the same family.
Castelo Rueda MP; Gilmozzi V; Riekschnitz DA; Di Segni M; Silipigni R; Pramstaller PP; Hicks AA; Pichler I; Zanon A
Stem Cell Res; 2022 Apr; 60():102692. PubMed ID: 35121197
[TBL] [Abstract][Full Text] [Related]
3. Generation of an induced pluripotent stem cell line (CSC-44) from a Parkinson's disease patient carrying a compound heterozygous mutation (c.823C>T and EX6 del) in the PARK2 gene.
Marote A; Pomeshchik Y; Goldwurm S; Collin A; Lamas NJ; Pinto L; Salgado AJ; Roybon L
Stem Cell Res; 2018 Mar; 27():90-94. PubMed ID: 29353703
[TBL] [Abstract][Full Text] [Related]
4. Generation of hiPSCs (JUCGRMi003-A) from a patient with Parkinson's disease with PARK2 mutation.
Ishikawa KI; Okuzumi A; Yoshino H; Hattori N; Akamatsu W
Stem Cell Res; 2024 Apr; 76():103323. PubMed ID: 38309147
[TBL] [Abstract][Full Text] [Related]
5. Generation of an induced pluripotent stem cell line (EURACi005-A) from a Parkinson's disease patient carrying a homozygous exon 3 deletion in the PRKNgene.
Zanon A; Riekschnitz D; von Troyer M; Volpato C; Picard A; Cantaloni C; Di Segni M; Silipigni R; Pramstaller PP; Hicks AA; Pichler I
Stem Cell Res; 2019 Dec; 41():101624. PubMed ID: 31715428
[TBL] [Abstract][Full Text] [Related]
6. Generation of induced pluripotent stem cells (NIMHi015-A) from a Parkinson's Disease patient harbouring a homozygous Exon 3 deletion in the PRKN gene.
Banerjee R; Ghanty R; Jagtap S; Holla V; Kamble N; Yadav R; Pal PK; Datta I
Stem Cell Res; 2024 Jun; 77():103440. PubMed ID: 38739971
[TBL] [Abstract][Full Text] [Related]
7. Heterozygous PRKN mutations are common but do not increase the risk of Parkinson's disease.
Zhu W; Huang X; Yoon E; Bandres-Ciga S; Blauwendraat C; Billingsley KJ; Cade JH; Wu BP; Williams VH; Schindler AB; Brooks J; Gibbs JR; Hernandez DG; Ehrlich D; Singleton AB; Narendra DP
Brain; 2022 Jun; 145(6):2077-2091. PubMed ID: 35640906
[TBL] [Abstract][Full Text] [Related]
8. Generation of a PARK2 homozygous knockout induced pluripotent stem cell line (GIBHi002-A-1) with two common isoforms abolished.
Zhang M; Ibañez DP; Fan W; Liu H; Zhong X; Wang X; Li Y; Md Abdul M; Li W; Li Y; Ward C; Chen S; Wang D; Qin B; Esteban MA; Zhao P; Luo Z
Stem Cell Res; 2019 Dec; 41():101602. PubMed ID: 31698191
[TBL] [Abstract][Full Text] [Related]
9. Transcriptional alterations in skin fibroblasts from Parkinson's disease patients with parkin mutations.
González-Casacuberta I; Morén C; Juárez-Flores DL; Esteve-Codina A; Sierra C; Catalán-García M; Guitart-Mampel M; Tobías E; Milisenda JC; Pont-Sunyer C; Martí MJ; Cardellach F; Tolosa E; Artuch R; Ezquerra M; Fernández-Santiago R; Garrabou G
Neurobiol Aging; 2018 May; 65():206-216. PubMed ID: 29501959
[TBL] [Abstract][Full Text] [Related]
10. Generation of three induced pluripotent stem cell lines from a Parkinson's disease patient with mutant PARKIN (p. C253Y).
Tariq M; Liu H; Ibañez DP; Li Y; Chen S; Jiang M; Fan W; Zhao P; Luo Z; Wang D; Kanwal S
Stem Cell Res; 2020 May; 45():101822. PubMed ID: 32387897
[TBL] [Abstract][Full Text] [Related]
11. Generation of two human induced pluripotent stem cell lines from fibroblasts of Parkinson's disease patients carrying the ILE368ASN mutation in PINK1 (LCSBi002) and the R275W mutation in Parkin (LCSBI004).
Novak G; Finkbeiner S; Skibinski G; Bernini M; Donato C; Skupin A
Stem Cell Res; 2022 May; 61():102765. PubMed ID: 35378365
[TBL] [Abstract][Full Text] [Related]
12. Generation of homozygous PRKN, PINK1 and double PINK1/PRKN knockout cell lines from healthy induced pluripotent stem cells using CRISPR/Cas9 editing.
Chen CX; You Z; Abdian N; Sirois J; Shlaifer I; Tabatabaei M; Boivin MN; Gaborieau L; Karamchandani J; Beitel LK; Fon EA; Durcan TM
Stem Cell Res; 2022 Jul; 62():102806. PubMed ID: 35561458
[TBL] [Abstract][Full Text] [Related]
13. Generation of induced pluripotent stem cell line (ZZUi007-A) from a 52-year-old patient with a novel CHCHD2 gene mutation in Parkinson's disease.
Wang Y; Wang Z; Sun H; Mao C; Yang J; Liu Y; Liu H; Zhang S; Zhang J; Xu Y; Shi C
Stem Cell Res; 2018 Oct; 32():87-90. PubMed ID: 30237140
[TBL] [Abstract][Full Text] [Related]
14. The endoplasmic reticulum-mitochondria interface is perturbed in PARK2 knockout mice and patients with PARK2 mutations.
Gautier CA; Erpapazoglou Z; Mouton-Liger F; Muriel MP; Cormier F; Bigou S; Duffaure S; Girard M; Foret B; Iannielli A; Broccoli V; Dalle C; Bohl D; Michel PP; Corvol JC; Brice A; Corti O
Hum Mol Genet; 2016 Jul; 25(14):2972-2984. PubMed ID: 27206984
[TBL] [Abstract][Full Text] [Related]
15. [Etiology and pathogenesis of Parkinson's disease: from mitochondrial dysfunctions to familial Parkinson's disease].
Hattori N
Rinsho Shinkeigaku; 2004; 44(4-5):241-62. PubMed ID: 15287506
[TBL] [Abstract][Full Text] [Related]
16. Identification of bioactive metabolites in human iPSC-derived dopaminergic neurons with PARK2 mutation: Altered mitochondrial and energy metabolism.
Okarmus J; Havelund JF; Ryding M; Schmidt SI; Bogetofte H; Heon-Roberts R; Wade-Martins R; Cowley SA; Ryan BJ; Færgeman NJ; Hyttel P; Meyer M
Stem Cell Reports; 2021 Jun; 16(6):1510-1526. PubMed ID: 34048689
[TBL] [Abstract][Full Text] [Related]
17. Generation of an induced pluripotent stem cell line (CSC-32) from a patient with Parkinson's disease carrying a heterozygous variation p.A53T in the SNCA gene.
Azevedo C; Chumarina M; Serafimova E; Goldwurm S; Collin A; Roybon L; Savchenko E; Pomeshchik Y
Stem Cell Res; 2020 Mar; 43():101694. PubMed ID: 31954327
[TBL] [Abstract][Full Text] [Related]
18. Long-Read Sequencing Resolves a Complex Structural Variant in PRKN Parkinson's Disease.
Daida K; Funayama M; Billingsley KJ; Malik L; Miano-Burkhardt A; Leonard HL; Makarious MB; Iwaki H; Ding J; Gibbs JR; Ishiguro M; Yoshino H; Ogaki K; Oyama G; Nishioka K; Nonaka R; Akamatsu W; Blauwendraat C; Hattori N
Mov Disord; 2023 Dec; 38(12):2249-2257. PubMed ID: 37926948
[TBL] [Abstract][Full Text] [Related]
19. Generation and characterization of induced pluripotent stem cells from a Parkinson's disease patient carrying the digenic LRRK2 p.G2019S and GBA1 p.N409S mutations.
Oleksy C; Massart F; Goldwurm S; Arado A; Arena G; Boussaad I; Krüger R
Stem Cell Res; 2023 Oct; 72():103212. PubMed ID: 37832355
[TBL] [Abstract][Full Text] [Related]
20. Generation of an induced pluripotent stem cell line (CSC-46) from a patient with Parkinson's disease carrying a novel p.R301C mutation in the GBA gene.
Gustavsson N; Marote A; Pomeshchik Y; Russ K; Azevedo C; Chumarina M; Goldwurm S; Collin A; Pinto L; Salgado AJ; Klementieva O; Roybon L; Savchenko E
Stem Cell Res; 2019 Jan; 34():101373. PubMed ID: 30640063
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
